274 related articles for article (PubMed ID: 10421439)
21. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity.
Vellom DC; Radić Z; Li Y; Pickering NA; Camp S; Taylor P
Biochemistry; 1993 Jan; 32(1):12-7. PubMed ID: 8418833
[TBL] [Abstract][Full Text] [Related]
22. Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases.
Saxena A; Qian N; Kovach IM; Kozikowski AP; Pang YP; Vellom DC; Radić Z; Quinn D; Taylor P; Doctor BP
Protein Sci; 1994 Oct; 3(10):1770-8. PubMed ID: 7849595
[TBL] [Abstract][Full Text] [Related]
23. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.
Kryger G; Silman I; Sussman JL
Structure; 1999 Mar; 7(3):297-307. PubMed ID: 10368299
[TBL] [Abstract][Full Text] [Related]
24. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
Campiani G; Fattorusso C; Butini S; Gaeta A; Agnusdei M; Gemma S; Persico M; Catalanotti B; Savini L; Nacci V; Novellino E; Holloway HW; Greig NH; Belinskaya T; Fedorko JM; Saxena A
J Med Chem; 2005 Mar; 48(6):1919-29. PubMed ID: 15771436
[TBL] [Abstract][Full Text] [Related]
25. Toluidine blue O is a potent inhibitor of human cholinesterases.
Biberoglu K; Tek MY; Ghasemi ST; Tacal O
Arch Biochem Biophys; 2016 Aug; 604():57-62. PubMed ID: 27296777
[TBL] [Abstract][Full Text] [Related]
26. Acetylcholinesterase active centre and gorge conformations analysed by combinatorial mutations and enantiomeric phosphonates.
Kovarik Z; Radić Z; Berman HA; Simeon-Rudolf V; Reiner E; Taylor P
Biochem J; 2003 Jul; 373(Pt 1):33-40. PubMed ID: 12665427
[TBL] [Abstract][Full Text] [Related]
27. 4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields.
Vitorović-Todorović MD; Juranić IO; Mandić LM; Drakulić BJ
Bioorg Med Chem; 2010 Feb; 18(3):1181-93. PubMed ID: 20061157
[TBL] [Abstract][Full Text] [Related]
28. Specificity and orientation of trigonal carboxyl esters and tetrahedral alkylphosphonyl esters in cholinesterases.
Hosea NA; Berman HA; Taylor P
Biochemistry; 1995 Sep; 34(36):11528-36. PubMed ID: 7547883
[TBL] [Abstract][Full Text] [Related]
29. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Wadkins RM; Silman I; Sussman JL; Potter PM
Chem Biol Interact; 2005 Dec; 157-158():153-7. PubMed ID: 16289500
[TBL] [Abstract][Full Text] [Related]
30. Inhibition pathways of the potent organophosphate CBDP with cholinesterases revealed by X-ray crystallographic snapshots and mass spectrometry.
Carletti E; Colletier JP; Schopfer LM; Santoni G; Masson P; Lockridge O; Nachon F; Weik M
Chem Res Toxicol; 2013 Feb; 26(2):280-9. PubMed ID: 23339663
[TBL] [Abstract][Full Text] [Related]
31. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.
Komloova M; Musilek K; Horova A; Holas O; Dohnal V; Gunn-Moore F; Kuca K
Bioorg Med Chem Lett; 2011 Apr; 21(8):2505-9. PubMed ID: 21397501
[TBL] [Abstract][Full Text] [Related]
32. The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors.
Ariel N; Ordentlich A; Barak D; Bino T; Velan B; Shafferman A
Biochem J; 1998 Oct; 335 ( Pt 1)(Pt 1):95-102. PubMed ID: 9742217
[TBL] [Abstract][Full Text] [Related]
33. Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.
Kia Y; Osman H; Kumar RS; Basiri A; Murugaiyah V
Bioorg Med Chem; 2014 Feb; 22(4):1318-28. PubMed ID: 24461561
[TBL] [Abstract][Full Text] [Related]
34. Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
Butini S; Campiani G; Borriello M; Gemma S; Panico A; Persico M; Catalanotti B; Ros S; Brindisi M; Agnusdei M; Fiorini I; Nacci V; Novellino E; Belinskaya T; Saxena A; Fattorusso C
J Med Chem; 2008 Jun; 51(11):3154-70. PubMed ID: 18479118
[TBL] [Abstract][Full Text] [Related]
35. In-silico identification of the binding mode of synthesized adamantyl derivatives inside cholinesterase enzymes.
Al-Aboudi A; Al-Qawasmeh RA; Shahwan A; Mahmood U; Khalid A; Ul-Haq Z
Acta Pharmacol Sin; 2015 Jul; 36(7):879-86. PubMed ID: 25937631
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of two different cholinesterases by tacrine.
Ahmed M; Rocha JB; Corrêa M; Mazzanti CM; Zanin RF; Morsch AL; Morsch VM; Schetinger MR
Chem Biol Interact; 2006 Aug; 162(2):165-71. PubMed ID: 16860785
[TBL] [Abstract][Full Text] [Related]
37. Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase.
Bosak A; Opsenica DM; Šinko G; Zlatar M; Kovarik Z
Chem Biol Interact; 2019 Aug; 308():101-109. PubMed ID: 31100281
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors.
Makhaeva GF; Boltneva NP; Lushchekina SV; Serebryakova OG; Stupina TS; Terentiev AA; Serkov IV; Proshin AN; Bachurin SO; Richardson RJ
Bioorg Med Chem; 2016 Mar; 24(5):1050-62. PubMed ID: 26827140
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, structure-activity relationship and molecular docking studies of 3-O-flavonol glycosides as cholinesterase inhibitors.
Mughal EU; Javid A; Sadiq A; Murtaza S; Zafar MN; Khan BA; Sumrra SH; Tahir MN; Kanwal ; Khan KM
Bioorg Med Chem; 2018 Jul; 26(12):3696-3706. PubMed ID: 29886083
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in silico analysis of novel astaxanthin-s-allyl cysteine as an inhibitor of butyrylcholinesterase and various globular forms of acetylcholinesterases.
Sakayanathan P; Loganathan C; Kandasamy S; Ramanna RV; Poomani K; Thayumanavan P
Int J Biol Macromol; 2019 Nov; 140():1147-1157. PubMed ID: 31442505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
